In a small cohort of lupus patients, GLP-1 receptor agonists did not trigger disease flares and produced significant BMI reductions of up to 13% over 6–10 months.
13% BMI reduction at 6-10 monthsLupus patients on GLP-1 receptor agonists achieved significant weight loss without triggering disease flares, though only 18 patients were studied.
What the researchers found
Among 18 lupus patients treated with GLP-1 receptor agonists from the NYU Lupus Cohort, only one mild-to-moderate flare occurred at 6–10 months, and no patients accumulated new SLE classification criteria during follow-up. The flare rate was within expected background rates for the disease.
BMI reductions were statistically significant: median BMI decreased by 3% at 1–4 months (P = 0.002) and by 13% at 6–10 months (P = 0.001). Notably, 9 of 18 patients (50%) were initially denied insurance coverage for their GLP-1RA prescription. Only 24 of 1,211 patients (2%) in the entire lupus cohort had received a GLP-1RA, suggesting significant underutilization.
Why it matters
Lupus patients face elevated cardiovascular risk and metabolic complications, making GLP-1RAs potentially valuable. However, a published case of drug-induced lupus from GLP-1RA use created uncertainty about safety in this population. This small but important study provides initial reassurance that these drugs don't appear to trigger lupus flares, while delivering meaningful weight loss — potentially addressing both metabolic and cardiovascular risks in SLE patients.
How the study worked
This was a retrospective analysis of patients in the NYU Lupus Cohort who had used a GLP-1 receptor agonist. Of 1,211 cohort patients, 24 had received a GLP-1RA; 6 were excluded due to insufficient documentation, leaving 18 for analysis. Patient characteristics, disease activity, and BMI were assessed at baseline (most recent rheumatology visit before starting GLP-1RA), 1–4 months, and 6–10 months after initiation.
What this study cannot tell us
This is a very small (n=18), single-center, retrospective, descriptive study without a control group. The sample size is insufficient to detect uncommon adverse events or statistically rare lupus flares. The follow-up period (6–10 months) is short relative to the chronic nature of SLE. Selection bias is likely — patients chosen for GLP-1RA therapy may have had more stable disease. The study cannot distinguish whether the low flare rate is because GLP-1RAs are truly safe in lupus or because the sample was too small and follow-up too short to detect problems.
How to read the evidence
This is a small, single-center, retrospective descriptive study — the lowest level of clinical evidence. While the safety signal is reassuring, the sample size (n=18) is too small for definitive conclusions. The study primarily generates hypotheses for future prospective research.
When this study was published
Published in 2025 in Rheumatology (Oxford), this is a very timely study addressing an emerging clinical question as GLP-1RA prescribing expands to populations not well represented in original clinical trials.
The bigger picture
Autoimmune disease patients have historically been excluded from or underrepresented in GLP-1RA clinical trials, creating a knowledge gap about safety in these populations. As GLP-1RAs become more widely prescribed, understanding their safety in patients with lupus, rheumatoid arthritis, and other autoimmune conditions is critical. Some researchers even hypothesize that GLP-1 drugs may have anti-inflammatory properties that could benefit autoimmune disease — but that remains to be proven.
Questions still open
- Would a larger, prospective study confirm the safety of GLP-1RAs in lupus, and might they actually reduce cardiovascular risk in this high-risk population?
- Why were only 2% of lupus cohort patients prescribed GLP-1RAs — is this driven by safety concerns, insurance barriers, or both?
- Could GLP-1 receptor agonists have anti-inflammatory effects that might benefit lupus disease activity beyond metabolic improvements?
Common questions
Are GLP-1 weight loss drugs safe for people with lupus?
Why might GLP-1 drugs be particularly useful for lupus patients?
Read the original research
A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.
Rheumatology (Oxford, England), 64(5), 3085-3089
Citation
Carlucci, Philip M; Cohen, Brooke; Saxena, Amit; Belmont, H Michael; Masson, Mala; Gold, Heather T; Buyon, Jill; Izmirly, Peter. (2025). A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.. Rheumatology (Oxford, England), 64(5), 3085-3089. https://doi.org/10.1093/rheumatology/keae547